{"drugs":["Adenovirus Type 4 and Type 7 Vaccine, Live"],"mono":{"0":{"id":"930620-s-0","title":"Generic Names","mono":"Adenovirus Type 4 and Type 7 Vaccine, Live"},"1":{"id":"930620-s-1","title":"Dosing and Indications","sub":{"0":{"id":"930620-s-1-4","title":"Adult Dosing","mono":"<b>Adenoviral respiratory disease, Acute, febrile, Type 4 and 7; Prophylaxis:<\/b> 17 to 50 years of age serving in the military: single vaccine dose as 2 tablets orally (1 tablet of Adenovirus Type 4 and 1 tablet of Adenovirus Type 7) "},"1":{"id":"930620-s-1-5","title":"Pediatric Dosing","mono":"<b>Adenoviral respiratory disease, Acute, febrile, Type 4 and 7; Prophylaxis:<\/b> 17 years and older serving in the military: single vaccine dose as 2 tablets orally (1 tablet of Adenovirus Type 4 and 1 tablet of Adenovirus Type 7) "},"3":{"id":"930620-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Adenoviral respiratory disease, Acute, febrile, Type 4 and 7; Prophylaxis<br\/>"}}},"3":{"id":"930620-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930620-s-3-9","title":"Contraindications","mono":"<ul><li>inability to swallow entire tablet whole, without chewing; chewing could expose upper respiratory tract to live adenovirus leading to disease<\/li><li>pregnancy; avoid pregnancy for 6 weeks following administration<\/li><li>severe allergic reaction (anaphylaxis) to any component<\/li><\/ul>"},{"id":"930620-s-3-10","title":"Precautions","mono":"<ul><li>infectious agent risk, including viruses and theoretical risk of Creutzfeldt-Jakob disease; vaccine is human plasma derivative (albumin)<\/li><li>viral shedding and transmission occurs; avoid contact with children (less than 7 years of age), immunocompromised patients, or pregnant women for 28 days following administration<\/li><li>report suspected adverse reactions to Teva Women's Health at 1-866-832-8537 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov<\/li><\/ul>"},{"id":"930620-s-3-11","title":"Pregnancy Category","mono":"Fetal risk cannot be ruled out. (TH)<br\/>"},{"id":"930620-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk is minimal.<br\/>"}]},"4":{"id":"930620-s-4","title":"Drug Interactions","sub":{"1":{"id":"930620-s-4-14","title":"Major","mono":"<ul><li>Aclarubicin (established)<\/li><li>Adalimumab (theoretical)<\/li><li>Aldesleukin (established)<\/li><li>Altretamine (established)<\/li><li>Amonafide (established)<\/li><li>Amsacrine (established)<\/li><li>Asparaginase (established)<\/li><li>Azacitidine (established)<\/li><li>Azathioprine (established)<\/li><li>Bleomycin (established)<\/li><li>Broxuridine (established)<\/li><li>Busulfan (established)<\/li><li>Capecitabine (established)<\/li><li>Carboplatin (established)<\/li><li>Carmustine (established)<\/li><li>Certolizumab Pegol (theoretical)<\/li><li>Chlorambucil (established)<\/li><li>Cisplatin (established)<\/li><li>Cladribine (established)<\/li><li>Cyclophosphamide (established)<\/li><li>Cytarabine (established)<\/li><li>Cytarabine Liposome (established)<\/li><li>Dacarbazine (established)<\/li><li>Dactinomycin (established)<\/li><li>Daunorubicin (established)<\/li><li>Daunorubicin Citrate Liposome (established)<\/li><li>Decitabine (established)<\/li><li>Docetaxel (established)<\/li><li>Doxifluridine (established)<\/li><li>Doxorubicin (established)<\/li><li>Doxorubicin Hydrochloride Liposome (established)<\/li><li>Edatrexate (established)<\/li><li>Eflornithine (established)<\/li><li>Epirubicin (established)<\/li><li>Estramustine (established)<\/li><li>Etanercept (established)<\/li><li>Etoposide (established)<\/li><li>Everolimus (theoretical)<\/li><li>Fingolimod (theoretical)<\/li><li>Floxuridine (established)<\/li><li>Fludarabine (established)<\/li><li>Fluorouracil (established)<\/li><li>Fotemustine (established)<\/li><li>Gallium Nitrate (established)<\/li><li>Gemcitabine (established)<\/li><li>Golimumab (theoretical)<\/li><li>Hydroxyurea (established)<\/li><li>Idarubicin (established)<\/li><li>Ifosfamide (established)<\/li><li>Immune Globulin (probable)<\/li><li>Infliximab (theoretical)<\/li><li>Irinotecan (established)<\/li><li>Lomustine (established)<\/li><li>Mechlorethamine (established)<\/li><li>Melphalan (established)<\/li><li>Mercaptopurine (established)<\/li><li>Methotrexate (established)<\/li><li>Mitolactol (established)<\/li><li>Mitomycin (established)<\/li><li>Mitotane (established)<\/li><li>Mitoxantrone (established)<\/li><li>Mycophenolic Acid (theoretical)<\/li><li>Oxaliplatin (established)<\/li><li>Paclitaxel (established)<\/li><li>Pegaspargase (established)<\/li><li>Pentostatin (established)<\/li><li>Pipobroman (established)<\/li><li>Pirarubicin (established)<\/li><li>Plicamycin (established)<\/li><li>Procarbazine (established)<\/li><li>Raltitrexed (established)<\/li><li>Rilonacept (theoretical)<\/li><li>Rituximab (established)<\/li><li>Secukinumab (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>Sirolimus (probable)<\/li><li>Streptozocin (established)<\/li><li>Teceleukin (established)<\/li><li>Tegafur (established)<\/li><li>Temsirolimus (theoretical)<\/li><li>Teniposide (established)<\/li><li>Thioguanine (established)<\/li><li>Thiotepa (established)<\/li><li>Topotecan (established)<\/li><li>Trabectedin (theoretical)<\/li><li>Treosulfan (established)<\/li><li>Trimetrexate (established)<\/li><li>Trofosfamide (established)<\/li><li>Uracil Mustard (established)<\/li><li>Ustekinumab (theoretical)<\/li><li>Vinblastine (established)<\/li><li>Vincristine (established)<\/li><li>Vincristine Sulfate Liposome (established)<\/li><li>Vindesine (established)<\/li><li>Vinorelbine (established)<\/li><\/ul>"},"2":{"id":"930620-s-4-15","title":"Moderate","mono":"<ul><li>Abatacept (probable)<\/li><li>Leflunomide (established)<\/li><\/ul>"}}},"5":{"id":"930620-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Diarrhea (3.1% to 10.2%), Nausea (5% to 13.6%)<\/li><li><b>Neurologic:<\/b>Headache (6.5% to 29.5%)<\/li><li><b>Respiratory:<\/b>Cough (8.5% to 12.4%), Nasal congestion (7.6% to 15.3%), Pain in throat (8.4% to 12.9%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Gastrointestinal:<\/b>Gastritis, Gastroenteritis, Gastroenteritis, Febrile, Hematochezia<\/li><li><b>Renal:<\/b>Hematuria<\/li><li><b>Respiratory:<\/b>Pneumonia<\/li><\/ul>"},"6":{"id":"930620-s-6","title":"Drug Name Info","sub":{"2":{"id":"930620-s-6-19","title":"Class","mono":"Vaccine<br\/>"},"3":{"id":"930620-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"930620-s-7","title":"Mechanism Of Action","mono":"the Adenovirus Type 4 and Type 7 oral vaccine is a live, non-attenuated vaccine derived from human-diploid fibroblast cell cultures (strain WI-38), and contains at least 32,000 tissue culture infective doses of either virus per tablet. Although the exact mechanism of live adenovirus vaccine is unclear, the virus replicates in the intestinal tract and induces immunity in person with low or no pre-existing neutralizing antibodies.<br\/>"},"9":{"id":"930620-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>swallow each tablet whole, do not chew or crush<\/li><li>postpone vaccination in individuals with vomiting and\/or diarrhea<\/li><\/ul>"},"10":{"id":"930620-s-10","title":"Monitoring","mono":"no specific monitoring has been determined<br\/>"},"13":{"id":"930620-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to use adequate contraception to avoid pregnancy for 6 weeks following administration.<\/li><li>Counsel patient to avoid contact with children (less than 7 years of age), immunocompromised patients, or pregnant women for 28 days following administration due to viral shedding and potential viral transmission.<\/li><li>Instruct patient to wash hands frequently, especially following bowel movements, during the 28 days following administration to prevent viral transmission.<\/li><li>Drug may cause upper respiratory tract infections, headaches, nasal congestion, pharyngolaryngeal pain, cough, arthralgia, nausea, abdominal pain, diarrhea, and vomiting.<\/li><li>Swallow each tablet whole without chewing.<\/li><\/ul>"}}}